David Grainger
British life-sciences investor and drug developer, venture partner at Medicxi and chief executive of Methuselah Health.
সংক্ষিপ্ত তথ্য
কোনো মুক্ত লাইসেন্সধারী প্রতিকৃতি পাওয়া যায়নি
- বর্তমান পদবি
- Venture Partner, Medicxi; Chief Executive, Methuselah Health
- সংস্থা
- Medicxi
এই নিবন্ধটি এখনও এই ভাষায় উপলব্ধ নয়। নিচে এর ইংরেজি সংস্করণটি দেওয়া হলো।
David Grainger (born 12 October 1966) is a British life-sciences investor and drug developer. He is a co-founder and venture partner of Medicxi, a European venture capital firm focused on life sciences, having previously worked in the life-sciences practice of Index Ventures.
He is chief executive of Methuselah Health, a United Kingdom company applying proteomics to the development of treatments for age-related disease, and was formerly Chief Innovation Officer of Centessa Pharmaceuticals.
Grainger has co-founded and chaired several biotechnology companies, among them XO1, later acquired by Janssen Pharmaceuticals, and Morphogen-IX, and led investments including Padlock Therapeutics, acquired by Bristol-Myers Squibb. He has also written on the pharmaceutical industry for Forbes.
শিক্ষা
- University of Cambridge